Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 158.29 Billion KRW | 359.45% |
| 2022 | 34.45 Billion KRW | -28.34% |
| 2021 | 48.08 Billion KRW | -12.3% |
| 2020 | 54.82 Billion KRW | 52.86% |
| 2019 | 35.86 Billion KRW | 5.05% |
| 2018 | 34.14 Billion KRW | -45.51% |
| 2017 | 62.65 Billion KRW | 9.52% |
| 2016 | 57.21 Billion KRW | -10.18% |
| 2015 | 63.69 Billion KRW | 144.75% |
| 2014 | 26.02 Billion KRW | 27.04% |
| 2013 | 20.48 Billion KRW | -36.63% |
| 2012 | 32.32 Billion KRW | 675.3% |
| 2011 | 4.16 Billion KRW | 140.26% |
| 2010 | -10.35 Billion KRW | -443.55% |
| 2009 | 3.01 Billion KRW | -80.14% |
| 2008 | 15.17 Billion KRW | 123.77% |
| 2007 | 6.78 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 206.49 Billion KRW | 20.59% |
| 2024 Q1 | 171.24 Billion KRW | 8.18% |
| 2023 Q2 | 122.64 Billion KRW | 134.52% |
| 2023 Q3 | 100.05 Billion KRW | -18.42% |
| 2023 Q4 | 158.29 Billion KRW | 58.21% |
| 2023 FY | 158.29 Billion KRW | 359.45% |
| 2023 Q1 | 52.29 Billion KRW | 51.79% |
| 2022 Q4 | 34.45 Billion KRW | -21.19% |
| 2022 Q3 | 43.71 Billion KRW | -22.82% |
| 2022 Q2 | 56.63 Billion KRW | 48.88% |
| 2022 FY | 34.45 Billion KRW | -28.34% |
| 2022 Q1 | 38.04 Billion KRW | -20.88% |
| 2021 Q2 | 74.59 Billion KRW | 16.31% |
| 2021 Q3 | 66.12 Billion KRW | -11.36% |
| 2021 FY | 48.08 Billion KRW | -12.3% |
| 2021 Q1 | 64.13 Billion KRW | 16.99% |
| 2021 Q4 | 48.08 Billion KRW | -27.29% |
| 2020 Q3 | 45.86 Billion KRW | 50.92% |
| 2020 Q4 | 54.82 Billion KRW | 19.54% |
| 2020 Q2 | 30.38 Billion KRW | 10.0% |
| 2020 FY | 54.82 Billion KRW | 52.86% |
| 2020 Q1 | 27.62 Billion KRW | -22.98% |
| 2019 Q3 | 42.36 Billion KRW | -26.89% |
| 2019 Q1 | 56.76 Billion KRW | 66.26% |
| 2019 FY | 35.86 Billion KRW | 5.05% |
| 2019 Q2 | 57.94 Billion KRW | 2.08% |
| 2019 Q4 | 35.86 Billion KRW | -15.34% |
| 2018 Q1 | 41.79 Billion KRW | -33.3% |
| 2018 Q3 | 49.09 Billion KRW | 34.78% |
| 2018 FY | 34.14 Billion KRW | -45.51% |
| 2018 Q4 | 34.14 Billion KRW | -30.45% |
| 2018 Q2 | 36.42 Billion KRW | -12.85% |
| 2017 FY | 62.65 Billion KRW | 9.52% |
| 2017 Q2 | 45.9 Billion KRW | -26.03% |
| 2017 Q4 | 62.65 Billion KRW | 8.57% |
| 2017 Q3 | 57.71 Billion KRW | 25.72% |
| 2017 Q1 | 62.06 Billion KRW | 8.47% |
| 2016 Q1 | 55.04 Billion KRW | -13.57% |
| 2016 Q2 | 48.25 Billion KRW | -12.33% |
| 2016 Q3 | 39.65 Billion KRW | -17.82% |
| 2016 Q4 | 57.21 Billion KRW | 44.27% |
| 2016 FY | 57.21 Billion KRW | -10.18% |
| 2015 Q1 | 63.58 Billion KRW | 144.34% |
| 2015 Q4 | 63.69 Billion KRW | -7.89% |
| 2015 Q3 | 69.14 Billion KRW | 38.82% |
| 2015 FY | 63.69 Billion KRW | 144.75% |
| 2015 Q2 | 49.81 Billion KRW | -21.66% |
| 2014 Q3 | 25.91 Billion KRW | 10.62% |
| 2014 Q2 | 23.42 Billion KRW | 28.66% |
| 2014 FY | 26.02 Billion KRW | 27.04% |
| 2014 Q4 | 26.02 Billion KRW | 0.43% |
| 2014 Q1 | 18.2 Billion KRW | -11.12% |
| 2013 Q4 | 20.48 Billion KRW | 86.6% |
| 2013 Q2 | 25.26 Billion KRW | -3.22% |
| 2013 Q1 | 26.1 Billion KRW | -19.24% |
| 2013 FY | 20.48 Billion KRW | -36.63% |
| 2013 Q3 | 10.97 Billion KRW | -56.55% |
| 2012 Q1 | -16.1 Billion KRW | 0.0% |
| 2012 FY | 32.32 Billion KRW | 675.3% |
| 2012 Q4 | 32.32 Billion KRW | 0.0% |
| 2011 FY | 4.16 Billion KRW | 140.26% |
| 2011 Q3 | 4 Billion KRW | -21.18% |
| 2011 Q2 | 5.08 Billion KRW | 55.96% |
| 2011 Q1 | 3.25 Billion KRW | 131.46% |
| 2010 Q4 | -10.35 Billion KRW | -25.21% |
| 2010 Q3 | -8.27 Billion KRW | -18.02% |
| 2010 FY | -10.35 Billion KRW | -443.55% |
| 2010 Q1 | 1.1 Billion KRW | -63.19% |
| 2010 Q2 | -7 Billion KRW | -731.6% |
| 2009 Q1 | 16.19 Billion KRW | 6.68% |
| 2009 FY | 3.01 Billion KRW | -80.14% |
| 2009 Q4 | 3.01 Billion KRW | -63.05% |
| 2009 Q3 | 8.15 Billion KRW | -34.32% |
| 2009 Q2 | 12.42 Billion KRW | -23.28% |
| 2008 Q1 | -746.15 Million KRW | -111.0% |
| 2008 Q2 | 4.87 Billion KRW | 753.52% |
| 2008 Q3 | 8.09 Billion KRW | 66.06% |
| 2008 Q4 | 15.17 Billion KRW | 87.42% |
| 2008 FY | 15.17 Billion KRW | 123.77% |
| 2007 Q1 | 3.04 Billion KRW | 0.0% |
| 2007 FY | 6.78 Billion KRW | 0.0% |
| 2007 Q3 | -8.73 Billion KRW | -484.06% |
| 2007 Q2 | -1.49 Billion KRW | -149.2% |
| 2007 Q4 | 6.78 Billion KRW | 177.61% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1698.367% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 72.327% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 49.08% |
| HANDOK Inc. | 283.45 Billion KRW | 44.155% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -688.638% |
| Yuhan Corporation | -69.18 Billion KRW | 328.797% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 18.383% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 4394.757% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 69.434% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 588.089% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -109.181% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -329.718% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -91.828% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -530.453% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1698.367% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 199.03% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 21.224% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 7.398% |
| JW Holdings Corporation | 480.68 Billion KRW | 67.069% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 3.819% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -134584.615% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -2.543% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6632.255% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -588.204% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 9.531% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -204.566% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1698.367% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 55.805% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -2.543% |
| Yuhan Corporation | -69.18 Billion KRW | 328.797% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -16.402% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -165.268% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 63.114% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -2.543% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -36.185% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -863.749% |
| CKD Bio Corp. | 143.29 Billion KRW | -10.468% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -36.384% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 757.878% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 453.862% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6632.255% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 62.564% |
| Boryung Corporation | 187.72 Billion KRW | 15.678% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 320.346% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -109.181% |
| JW Lifescience Corporation | 26.09 Billion KRW | -506.717% |